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The development of methods for speciﬁc delivery of drugs is an important issue for many cancer therapy approaches. Most of
macromolecular drugs are taken into the cell through endocytosis and, being unable to escape from endocytic vesicles,
eventually are degraded there, which hinders their therapeutic usefulness. We have developed a method, called
photochemical internalization, based on light-induced photochemical reactions, disrupting endocytic vesicles speciﬁcally within
illuminated sites e.g. tumours. Here we present a new drug delivery concept based on photochemical internalization-principle
– photochemical disruption of endocytic vesicles before delivery of macromolecules, leading to an instant endosomal release
instead of detrimental stay of the molecules in endocytic vesicles. Previously we have shown that illumination applied after the
treatment with macromolecules substantially improved their biological effect both in vitro and in vivo. Here we demonstrate
that exposure to light before delivery of protein toxin gelonin improves gelonin effect in vitro much more than light after.
However, in vitro transfection with reporter genes delivered by non-viral and adenoviral vectors is increased more than 10-
and six-fold, respectively, by both photochemical internalization strategies. The possible cellular mechanisms involved, and the
potential of this new method for practical application of photochemical internalization concept in cancer therapy are discussed.
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Despite exciting progress in the development of new anticancer
agents, the development of appropriate delivery strategies, allowing
a therapeutic molecule to reach the target and express a therapeutic
function, remains to be one of the most important issues for
cancer therapy. Most of anticancer agents (e.g. protein- or nucleic
acid-based drugs, some watersoluble chemotherapeutics) are
membrane-impermeable big molecules, usually taken into the
target cell through the endocytic pathway. Moreover, to target
tumour cells, therapeutic molecules are often coupled to different
ligands, binding to speciﬁc receptors on tumour cells, which also
leads to receptor-mediated endocytosis (Dubowchik and Walker,
1999). However, macromolecules usually do not have means for
escaping from endocytic vesicles and consequently, degradation
inside these vesicles in many cases hinders their therapeutic appli-
cation (Lloyd, 2000). Thus, it is known that type I ribosome-
inactivating protein toxins could have a great potential as anti-
cancer agents if released from the vesicles (Barbieri et al, 1993).
Also, inefﬁcient endosomal release of therapeutic nucleic acids,
especially if delivered by non-viral vectors, is an important obstacle
for cancer gene therapy (Zabner et al, 1995; Luo and Saltzman,
2000). Therefore, the development of endosome-disruptive strate-
gies to liberate therapeutic macromolecules is of great
importance for the exploitation of full potential of anticancer
drugs.
Recently we have developed a new technology named photoche-
mical internalization (PCI) to improve the cytosolic delivery of
various macromolecules that are taken into the cell via endocytosis
(Berg et al, 1999). The method is based on the use of photosensi-
tizing compounds, such as aluminium phthalocyanine (AlPcS2a)
that localize in endocytic vesicles and upon light exposure induce
photochemical damage to the vesicular membranes, releasing intact
macromolecules into the cytosol (Berg et al, 1999). PCI, as a light-
dependent treatment, is an attractive approach for targeted drug
delivery, since in principal only areas exposed to light (e.g.
tumours) will be subjected to the drug effects.
We have reported earlier that the PCI principle can be utilized
in vitro for transfer of various macromolecules. Thus, the toxicity
of proteins, such as the type I ribosome-inactivating toxin gelonin
and a tumour-targeted immunotoxin, was considerably increased
by photochemical treatment (Berg et al, 1999; Selbo et al, 2000).
Likewise, the efﬁciency of transfection with a reporter transgene
was improved 10–20-fold by light (Høgset et al, 2000; Prasmick-
aite et al, 2000). We have also demonstrated the potential of the
PCI technology in vivo in an animal model, where the cytotoxic
effect of gelonin, which was completely inactive when used alone,
was increased tremendously by photochemical treatment, resulting
in a complete regression of subcutaneous tumours in mice (Selbo
et al, 2001).
Originally the PCI method was developed to liberate macromo-
lecules, which had already been endocytosed and trapped in
endocytic vesicles, i.e. it was based on illumination applied after
the treatment with macromolecules (‘light after’ strategy).
Although the technology generally works well in this setting, there
are several potential disadvantages: (i) the possible enzymatic
degradation of the macromolecules in endocytic vesicles before
the liberation; (ii) the possible induction of photochemical damage
to the macromolecules located close to the photosensitizer at the
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treatment in a therapeutic situation. Therefore, the aim of this
study was to investigate the possibility of disrupting endocytic vesi-
cles in advance, i.e. before the macromolecules are taken into the
cell (‘light before’ strategy). In this report we show that this novel
PCI approach can increase the biological effect of both protein
toxins and transfecting nucleic acids more or at least as efﬁciently
as our previously described strategy. The implication of the ﬁnd-
ings for the development of light-directed drug delivery systems
for cancer therapy will be discussed.
MATERIALS AND METHODS
Reagents and cell culture
A plasmid pEGFP-N1 (encoding Enhanced Green Fluorescent
Protein (EGFP)) was purchased from Clontech Laboratories, Inc.
(Palo Alto, CA, USA), AlPcS2a was from Porphyrin Products
(Logan, UT, USA). Gelonin, poly-L-lysine hydrobromide (MW
20700) and FITC-dextran (MW 4400) were from Sigma (St. Louis,
MO, USA). Fluorescein di-b-D-galactopyranoside was from Mole-
cular Probes (Eugene, OR, USA). Adenovirus AdHCMV-lacZ was
kindly provided by Dr FL Graham, McMaster University, Ontario,
Canada.
The human malignant melanoma cell line THX was established
from a tumour tissue obtained from a patient treated for metastatic
malignant melanoma at the Norwegian Radium Hospital. The cells
were cultured in RPMI-1640 medium supplemented with 10%
foetal calf serum, 100 units ml
71 penicillin, 100 mgm l
71 strepto-
mycin and 2 mM glutamine (all from Bio Whittaker,
Walkersville, MD, USA) at 378Ci n5 %C O 2 atmosphere.
Treatment with different macromolecules
For the treatment with gelonin 25610
3 cells per well were seeded
out into 24-well plates (Nunc, Denmark). For the transfection with
pEGFP-N1/polylysine and transduction with AdHCMV-lacZ
50610
3 THX cells per well were seeded out into 6-well plates.
The next day 20 mgm l
71 AlPcS2a were added, and the cells were
incubated for 18 h at 378C. All the procedures after AlPcS2a addi-
tion were carried on in subdued light. For the ‘light before’ strategy
AlPcS2a was removed, the cells were washed three times and incu-
bated in AlPcS2a-free medium for 4 h. Then the cells were exposed
to light (see below) before the treatment with selected macromole-
cules: either with gelonin (1 mgm l
71 for 18 h), or with the
pEGFP-N1/polylysine complex (5 mgm l
71 pEGFP-N1, for differ-
ent time depending on the experiment), or with AdHCMV-lacZ
(at a multiplicity of infection (MOI) 1 for 30 min). For the ‘light
after’ strategy the cells were ﬁrst treated with the selected macro-
molecules at the same concentrations and for the same time as
indicated above, washed, and after addition of fresh culture
medium exposed to light. Non-illuminated cells were treated in a
similar way except for illumination.
The treated cells were washed once with culture medium, and
after addition of fresh medium incubated at 378C before further
analysis. Inhibition of protein synthesis was assayed by [
3H]leucine
incorporation into proteins 24 h after light exposure as previously
described (Llorente et al, 1998). EGFP and b-galactosidase expres-
sion was analyzed by ﬂow cytometry (see below) 2 days after
illumination.
Illumination was performed from a bench of four light tubes
(Philips TLD 18W/79) and a long pass ﬁlter with a cut off at
550–600 nm. The light intensity reaching the cells was
13.5 W m
72. Light dose used for transgene delivery induces
approximately 50% toxicity (i.e. D50).
pEGFP-N1/polylysine complex (charge ratio 1.7) was prepared
by gently mixing plasmid and polylysine solutions prepared sepa-
rately: 5 mg pEGFP-N1 plasmid was diluted in 75 ml water and
5.3 mg polylysine diluted in 75 ml water. The solutions were mixed
and incubated for 30 min at room temperature, diluted with
culture medium to 1 ml and added to the cells.
Flow cytometry analysis
For the detection of EGFP, the cells were resuspended in 400 mlo f
culture medium and analyzed by a FACS-Calibur ﬂow cytometer
(Becton Dickinson, San Jose, CA, USA). For each sample 10 000
events were collected. EGFP was measured through a 510–
530 nm ﬁlter after excitation with an argon laser (15 mW,
488 nm). Dead cells were discriminated from single viable cells
by gating on forward scattering vs side scattering. The data were
analyzed with CELLQuest Software (Becton Dickinson).
The expression of b-galactosidase was measured as previously
described (Nolan et al, 1988). Brieﬂy, the cells were resuspended
in 25 ml of culture medium and incubated for 5 min at 378C.
25 mlo f2 m M ﬂuorescein di-b-D-galactopyranoside were added
and incubated for 1 min at 378C. The suspension was diluted by
adding 450 ml ice cold culture medium, and the samples were
maintained on ice for 30–60 min before analysis by ﬂow cytome-
try using the same settings as described above.
Fluorescence microscopy
THX cells were seeded out into Falcon 3001 dishes (25610
3 cells
per dish) and the next day treated with 20 mgm l
71 AlPcS2a for
18 h, washed and incubated in AlPcS2a-free medium for 4 h. Then
the cells were exposed to light for 4 min before a 3 h incubation
with 5 mg ml
71 FITC-dextran. Non-illuminated cells were treated
in a similar way except for illumination. The intracellular localiza-
tion of FITC-dextran in unﬁxed cells was observed with a Zeiss
Axioplan ﬂuorescence microscope (Oberkochen, Germany) using
an objective with 636magniﬁcation, a 450–490 nm band pass
excitation ﬁlter and a 510–540 band pass emission ﬁlter. Fluores-
cence micrographs were recorded by means of a cooled charge-
coupled device (CCD) camera (Photometrics Inc., Tucson, AZ,
USA).
RESULTS
Effect of photochemical treatment on the intracellular
localization of an endocytic marker
First we studied by ﬂuorescence microscopy, whether photochemi-
cal treatment applied before the incubation with an endocytic
marker (FITC-dextran) affects the intracellular localization of the
marker. As can be seen in Figure 1A, cells that were treated with
AlPcS2a and FITC-dextran in the absence of light show granular
FITC ﬂuorescence, indicating, as expected, localization of FITC-
dextran in endocytic vesicles. In contrast, exposure to light before
the incubation with FITC-dextran leads to diffuse FITC ﬂuores-
cence (Figure 1B), suggesting that a substantial fraction of FITC-
dextran entered the cytosol instead of accumulating in endocytic
vesicles. However, when AlPcS2a-treated cells were exposed to light
followed by incubation with FITC-dextran at 48C, when endocytic
uptake is inhibited, no intracellular FITC ﬂuorescence was detected
(data not shown), indicating that: (i) endocytosis is important for
the uptake of FITC-dextran into photochemically treated cells; (ii)
photochemical treatment does not permeabilize cellular membrane
so that FITC-dextran could passively diffuse into the cell cytosol.
Effect of photochemical treatment on the cytotoxic effect of
gelonin
The protein toxin gelonin is taken into the cell via endocytosis, but
is trapped in endocytic vesicles and ﬁnally degraded, therefore it is
relatively non-toxic to intact cells. However, in cell-free systems
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that the inability to escape from endocytic vesicles is the major
cause for the low toxicity to intact cells (Stirpe et al, 1980). As
can be seen in Figure 2, gelonin had no effect on protein synthesis
when applied in the absence of photochemical treatment. However,
exposure of AlPcS2a-treated cells to light before the incubation with
gelonin considerably increased the cytotoxicity of gelonin. Compar-
ison of the ‘light before’ and the ‘light after’ approaches in THX
cells shows that gelonin exhibited much stronger toxicity when
light was applied before gelonin-treatment as compared to light
after (Figure 2).
Effect of photochemical treatment on gene transfection
The effect of photochemical treatment on delivery of transgenes
was studied by measuring the efﬁciency of transfection with a plas-
mid, containing a reporter EGFP-gene driven by the cyto-
megalovirus promoter. The cationic polypeptide poly-L-lysine was
used for DNA complexation, and the transfection efﬁciency was
evaluated measuring EGFP expression. As can be seen in Figure
3A, light exposure increased the amount of EGFP-positive cells
by 410-fold as compared to non-illuminated cells, irrespectively
of whether light was applied before or after the DNA complex.
Photochemical treatment employing either ‘light before’ or ‘light
after’ strategy also stimulated transfection mediated by the targeted
transfection agent transferrin-poly-L-lysine (data not shown).
Effect of photochemical treatment on adenovirus-mediated
gene transduction
In order to study the effect of illumination before gene transduc-
tion with viruses (the most used vectors in cancer gene therapy
clinical trials), we used the adenovirus AdHCMV-lacZ, containing
a b-galactosidase reporter gene controlled by the cytomegalovirus
promoter. The cells were pre-incubated with AlPcS2a followed by
light exposure before or after a 30 min incubation with
AdHCMV-lacZ. As can be seen in Figure 3B, the percentage of
b-galactosidase-expressing cells was increased approximately six-
fold by both light-treatments, as compared to control cells that
were infected with the adenovirus, but not exposed to light. Higher
virus doses (i.e. higher MOI) gave higher percentage of transducted
cells in both non-illuminated and photochemically treated cell
populations (data not shown), however, in general, fold-increase
achieved by photochemical treatment is the highest for low virus
doses.
Effect of illumination time point
For the potential use of PCI as a method for light-induced delivery
in vivo, it was important to deﬁne the ‘time window’ for achieving
the maximal effect. Thus, THX cells were given a 30 min pulse
with the DNA/polylysine complex and were illuminated at different
time points before or after the DNA pulse. As can be seen in Figure
4, transfection using the ‘light before’ strategy was most efﬁcient
when light was given right before the DNA complex. A 5 h delay
reduced the efﬁciency of transfection by approximately 50%,
suggesting that the transfection-enhancing effects induced by light
last for up to at least 5 h, albeit decreasing with time. For compar-
ison, using the ‘light after’ strategy, the highest amount of EGFP-
positive cells was obtained when light was applied immediately
after the DNA complex, indicating that both the DNA-treatment
and the light-treatment should be strongly co-ordinated in time,
optimally following each other without any delay.
DISCUSSION
In this study we present a new drug delivery principle – photoche-
mical disruption of endocytic vesicles in speciﬁc regions of the
body, for improving internalization of later applied macromolecu-
lar drugs. This photochemical method offers for cancer therapy a
way for obtaining drug effects speciﬁcally in tumour cells. The
technology can be used with various macromolecules that are taken
into the cell by endocytosis, and whose therapeutic activity is
normally hampered by the inability to escape from endocytic
vesicles. Unlike our earlier described method (Berg et al, 1999;
Høgset et al, 2000; Selbo et al, 2000, 2001), where illumination
was performed after the treatment with macromolecules (Figure
5A), and unlike most other methods for endosomal liberation,
the strategy presented in this paper suggests permeabilization of
endocytic vesicles before delivery of macromolecules, avoiding a
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Figure 1 Effect of photochemical treatment on intracellular localization
of FITC-dextran. (A,B) Fluorescence micrographs. THX cells were incu-
bated with 20 mgm l
71 AlPcS2a for 18 h followed by a 4 h incubation in
AlPcS2a-free medium. Then the cells were either kept in the darkness
(A) or exposed to light for 4 min (B) before a 3 h incubation with
5m gm l
71 FITC-dextran. (A',B') Phase contrast showing the morphology
of the corresponding cells.
1
0.1
R
e
l
a
t
i
v
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
0           25          50          75         100        125        150
Light exposure (s)
AIPcS2a+gel+light after
AIPcS2a+light before+gel
AIPcS2a
Gelonin
Figure 2 Effect of photochemical treatment on gelonin-induced inhibi-
tion of protein synthesis. For the ‘light before’ strategy the cells were ﬁrst
incubated with 20 mgm l
71 AlPcS2a for 18 h, then for another 4 h in AlPc-
S2a-free medium before exposure to light as indicated in the ﬁgure. After
illumination 1 mgm l
71 gelonin (gel) was added, and the cells were incu-
bated for 18 h. For the ‘light after’ strategy the cells were co-incubated with
20 mgm l
71 AlPcS2a and 1 mgm l
71 gelonin for 18 h before light exposure.
The control cells were treated only with 1 mgm l
71 gelonin for 18 h and
exposed to light, or only with 20 mgm l
71 AlPcS2a for 18 h, chased 4 h
in AlPcS2a-free medium and exposed to light. [
3H]leucine incorporation
into proteins was measured the day after the light-treatment. Data pre-
sented are the mean relative to non-illuminated cells. Data points represent
mean+s.e. of triplicates.
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cytic vesicles. In effect this leads to a very rapid relocalization of
the endocytosed macromolecules into the cytosol, and conse-
quently improves their biological effect. In this study we
demonstrate that ‘light before’ PCI can substantially enhance the
cytotoxicity of protein toxins as well as efﬁciency of gene transfec-
tion mediated by both non-viral and viral vectors.
There are several reasons why illumination before drug delivery
should be advantageous as compared to previously discussed ‘light
after’ strategy. Firstly, in most clinical situations it would be prac-
tically advantageous if the light-treatment and the administration
of the drugs could be performed as simultaneously as possible.
For example, employing the technology in combination with
surgery, as an adjuvant treatment of residual disease after surgical
removal of tumours, it would be a great advantage to apply both
the light-treatment and the therapeutic macromolecule at the end
of surgical procedures and immediately following each other. In
this case the ‘light before’ approach would be clearly advantageous
to the ‘light after’ strategy, where one would have to wait several
hours to ensure maximal uptake of the drug. Secondly, the ‘light
before’ strategy could be more optimal for delivery of intact macro-
molecules. Photochemical treatment can damage various
biomolecules (Jori and Spikes, 1984). Therefore photochemical
damage to the entrapped therapeutic molecules can not be ruled
out when light is applied after the molecules, and this could
decrease the positive effects of PCI. However, the primary photo-
chemical effects should not directly damage molecules that are
delivered into the cell after illumination. Thirdly, it is known that
photochemical treatment can at least partially inactivate degrada-
tive lysosomal enzymes or impair microtubules involved in
transport towards lysosomes (Berg and Moan, 1994, 1997), so that
if applied in advance, it could protect endocytosed macromolecules
from the possible lysosomal degradation by both these mechanisms.
In this study it has been shown that both the ‘light before’ and
the ‘light after’ PCI-strategies improve the ﬁnal biological effect of
delivered macromolecules, however which approach leads to the
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Figure 4 Effect of illumination time point on the efﬁciency of light-in-
duced transfection with pEGFP/polylysine. For the ‘light before’ strategy
AlPcS2a-pretreated THX cells were transferred into AlPcS2a-free medium
and incubated for 4 h before light exposure for 3 min. Following illumina-
tion the cells were either immediately incubated with pEGFP/polylysine
complex (5 mgm l
71 plasmid) for 30 min or chased in culture medium
for different periods (as indicated in the scheme) before a 30 min incuba-
tion with pEGFP/polylysine. For the ‘light after’ strategy AlPcS2a-treated cells
were transferred into AlPcS2a-free medium, incubated with pEGFP/polyly-
sine complex for 30 min and either immediately exposed to light or chased
for different periods in complex-free medium before illumination. After
treatments the cells were transferred into fresh culture medium and incu-
bated for 2 days before analysis of EGFP expression. The relative EGFP ex-
pression was calculated taking as 100% the percentage of EGFP-expressing
cells, when the pEGFP/polylysine-treatment and the light-treatment fol-
lowed each other without any chase (t=0). Data points represent
mean+s.e. of three experiments.
‘Light after’
II I
Light
‘Light before’
III
Light
V IV
A
B
M
M M
M M M
M M M
M
M
M
M M
M
Figure 5 Photochemical internalization: ‘light after’ and ‘light before’
induced cytosolic delivery of endocytosed macromolecules. (A) ‘Light
after’: both the photosensitizer (S) and the macromolecule (M) are endo-
cytosed and localize in the same endocytic vesicles (I). Light exposure in-
duces photochemical reactions, leading to the disruption of vesicular
membranes and resulting in cytosolic release of the macromolecules (II).
(B) ‘Light before’: light-induced disruption of vesicular membranes contain-
ing S (III) before M is endocytosed and localize in intact endocytic vesicles
(IV). Fusion between intact M-containing and photochemically disrupted S-
containing vesicles leads to the cytosolic release of the macromolecules (V).
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Figure 3 (A) Effect of photochemical treatment on transfection with
pEGFP-N1/polylysine complex. For the ‘light before’ strategy AlPcS2a-pre-
treated THX cells were incubated in AlPcS2a-free medium for 4 h before
light exposure for 3 min (corresponding approximate D50 dose). Following
illumination pEGFP-N1/polylysine (5 mgm l
71 plasmid) was added and the
cells were incubated for 4 h. For the ‘light after’ strategy AlPcS2a-treated
cells were transferred into AlPcS2a-free medium and incubated with the
pEGFP-N1/polylysine complex for 4 h, transferred into complex-free med-
ium and exposed to light. After 2 days the cells were analyzed for EGFP
expression. Each bar represents the mean+s.e. of 5–7 experiments. (B)
Transduction with AdHCMV-lacZ. For the ‘light before’ strategy AlPcS2a-
pretreated THX cells were incubated for another 4 h in AlPcS2a-free med-
ium before light exposure for 3 min (corresponding approximate D50
dose). Following illumination the cells were infected with AdHCMV-lacZ
(at MOI 1) for 30 min, 2 ml of medium was added and after 2 days the
cells were analyzed for b-galactosidase expression. For the ‘light after’ strat-
egy AlPcS2a-treated cells were incubated in AlPcS2a-free medium for 3 h
before a 30 min infection with AdHCMV-lacZ. After addition of 2 ml of
culture medium the cells were incubated for another 30 min before illumi-
nation. Two days later the cells were analyzed for b-galactosidase expres-
sion.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 652–657better result seems to depend on the macromolecules to be deliv-
ered. Thus, in the case of gelonin it seems to be more beneﬁcial
to apply ‘light before’ gelonin (Figure 2). However, in the case
of transgene, light-induced transfection mediated by both polyly-
sine and adenovirus was similar regardless of whether
illumination was performed before or after administration of the
transgene (Figure 3). The difference in response between these
two classes of molecules might be due to their different sensitivity,
either to enzymatic degradation in endocytic vesicles, or to the
photochemically induced damage. If gelonin is more sensitive to
these damaging effects than the transgene (that might be protected
by the carrier molecules: synthetic vectors or viruses), then the
‘light before’ approach might be especially beneﬁcial due to the
reasons discussed above. It should be mentioned that gelonin
and reporter transgenes were used as examples to demonstrate
the versatility and efﬁcacy of the technology. However, the method
is far from being optimized, and by use of other macromolecules
under optimal conditions even better effects could be expected.
It has already been shown the efﬁciency of ‘light after’ PCI strat-
egy in vivo in combination with gelonin (Selbo et al, 2001). The
results described in the present work show that, in addition to
the above mentioned practical advantages, the ‘light before’ strategy
with gelonin in vitro works substantially more efﬁciently, making
the presented new PCI concept worth further investigation. The
exact cellular mechanism behind ‘light before’-based delivery is
not known. One obvious possibility – the direct entry into the
cytosol through the plasma membrane of photochemically treated
cells – does not seem very likely, since the results argue against
photochemical permeabilization of the plasma membrane and
strongly indicate the involvement of endocytic transport.
Another alternative is endosomal release mediated by passive
diffusion. As discussed above, photochemical treatment, if applied
in advance, could protect endocytosed macromolecules from lyso-
somal degradation, so that functional macromolecules could release
from intact endocytic vesicles via slow diffusion. However, the very
rapid relocalization of FITC-dextran (Figure 1B) strongly suggests
the existence of other mechanisms than slow passive diffusion
responsible for PCI effect.
Thus, the likely mechanism behind ‘light before’ effects could be
a fusion between photochemically ruptured vesicles and intact vesi-
cles carrying the macromolecules, leading to endosomal release of
the molecules as described in Figure 5B. More detailed studies of
the light effects on transgene delivery revealed that for the ‘light
before’ approach the best result was obtained when light was
applied right before the DNA complex, while introducing a chase
period between illumination and the DNA-treatment reduces the
transfection efﬁciency (Figure 4). Possible reasons for this can be
either cellular repair or removal of photochemically disrupted vesi-
cles, so that the DNA is not redirected into the cytosol, but rather
stays in intact vesicles. Work is in progress in our laboratory to
prove these hypotheses.
The technology presented in this study represents an important
addition to the emerging ﬁeld of physically induced drug delivery
methods. There are several factors making the PCI-technology a
relatively tumour-speciﬁc method: (i) light, activating photosensiti-
zers and inducing photochemical reactions, can be directed
precisely to tumours; (ii) photosensitizers accumulate preferentially
in tumours as compared to normal tissue (Chan et al, 1990; Pass,
1993). It should also be emphasized that there is already signiﬁcant
clinical experience employing photochemical principles, namely in
photodynamic therapy (PDT), a quite speciﬁc approach used for
treatment of different tumour types (Dougherty et al, 1998). In
addition, the presented technology involves endocytosis and there-
fore it is very well suited for combination with other tumour-
targeting strategies like surface-targeting via ligand-receptor inter-
action for speciﬁc uptake into tumour cells. Although the limited
light penetration through the tissues might be a limitation, by
the use of ﬁbre optic devices it is possible to reach many sites also
within the body, such as the gastrointestinal tract, lungs, brain etc.
(Pass, 1993). Another factor, which might limit application of PCI
technology is cytotoxicity, inducible by photochemical treatment,
that was successfully exploited in PDT of cancer (Pass, 1993;
Dougherty et al, 1998). In this respect, an attractive approach could
be to use photochemically internalized therapeutic molecules (e.g.
toxins or suicide genes) as adjuvants for PDT, to destroy cancer
cells that were not efﬁciently killed by PDT. In this way deeper
tumour layers, where due to limited light penetration a lower
photochemical dose (consequently, lower toxicity) is obtained,
could be also affected. However, in general, to balance photoche-
mical dose is a very important task to exploit the full potential
that photochemical internalization offers for different therapies.
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